TNFRSF17 and neoplasm: Bispecific NK cell engagers are bispecific antibodies that redirect the NK cell compartment against the tumor cells via binding to a receptor on the NK cell surface such as CD16A, NKp30, or NKG2d and to a molecule on the surface of the malignant PCs, such as the BCMA or SLAM7 [171,172,173].